CLINICAL RESEARCH: HEART FAILURE
Comparison of Copeptin, B-Type Natriuretic Peptide, and Amino-Terminal Pro-B-Type Natriuretic Peptide in Patients With Chronic Heart FailurePrediction of Death at Different Stages of the Disease
Stephanie Neuhold, MD*,
Martin Huelsmann, MD*,*,
Guido Strunk, PhD ,
Brigitte Stoiser, MD ,
Joachim Struck, PhD ,
Nils G. Morgenthaler, MD,
Andreas Bergmann, PhD,
Deddo Moertl, MD*,
Rudolf Berger, MD* and
Richard Pacher, MD*
* Department of Cardiology, Medical University of Vienna, Vienna, Austria
Department of Infectious Diseases, Medical University of Vienna, Vienna, Austria
Research Institute for Health Care Management and Economics, University of Economics and Business Administration, Vienna, Austria
B.R.A.H.M.S. AG, Hennigsdorf, Germany.
Manuscript received December 20, 2007;
revised manuscript received March 10, 2008,
accepted March 18, 2008.
* Reprint requests and correspondence: Dr. Martin Huelsmann, Medical University of Vienna, Department of Cardiology, Waehringer Guertel 18-20, 1090 Vienna, Austria. (Email: martin.huelsmann{at}meduniwien.ac.at).
Objectives: This study sought to evaluate the predictive value of copeptin over the entire spectrum of heart failure (HF) and compare it to the current benchmark markers, B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP).
Background: Vasopressin has been shown to increase with the severity of chronic HF. Copeptin is a fragment of pre–pro-vasopressin that is synthesized and secreted in equimolar amounts to vasopressin. Both hormones have a short lifetime in vivo, similar to BNPs, but in contrast to vasopressin, copeptin is very stable in vitro. The predictive value of copeptin has been shown in advanced HF, where it was superior to BNP for predicting 24-month mortality.
Methods: This was a long-term observational study in 786 HF patients from the whole spectrum of heart failure (New York Heart Association [NYHA] functional class I to IV, BNP 688 ± 948 pg/ml [range 3 to 8,536 pg/ml], left ventricular ejection fraction 25 ± 10% [range 5% to 65%]).
Results: The NYHA functional class was the most potent single predictor of 24-month outcome in a stepwise Cox regression model. The BNP, copeptin, and glomerular filtration rate were related to NYHA functional class (p < 0.0001 for trend). Copeptin was the most potent single predictor of mortality in patients with NYHA functional class II (p < 0.0001) and class III (p < 0.0001). In NYHA functional class IV, the outcome of patients was best predicted by serum sodium, but again, copeptin added additional independent information.
Conclusions: Increased levels of copeptin are linked to excess mortality, and this link is maintained irrespective of the clinical signs of severity of the disease. Copeptin was superior to BNP or NT-proBNP in this study, but the markers seem to be closely related.
Key Words: BNP • vasopressin • heart failure • prognosis
|
Abbreviations and Acronyms
| | ANP = atrial natriuretic peptide | | BNP = brain natriuretic peptide | | GFR = glomerular filtration rate | | LVEF = left ventricular ejection fraction | | NT-proANP = N-terminal pro-atrial natriuretic peptide | | NT-proBNP = N-terminal pro-B-type natriuretic peptide | | NYHA = New York Heart Association | | ROC = receiver-operator characteristic |
|
Related Article
-
Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 52: A23-A24.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
W. L. Miller, K. A. Hartman, D. E. Grill, J. Struck, A. Bergmann, and A. S. Jaffe
Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure
Heart,
March 1, 2012;
98(5):
389 - 394.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Maisel, Y. Xue, K. Shah, C. Mueller, R. Nowak, W. F. Peacock, P. Ponikowski, M. Mockel, C. Hogan, A. H. B. Wu, et al.
Increased 90-Day Mortality in Patients With Acute Heart Failure With Elevated Copeptin: Secondary Results From the Biomarkers in Acute Heart Failure (BACH) Study
Circ Heart Fail,
September 1, 2011;
4(5):
613 - 620.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Tentzeris, R. Jarai, S. Farhan, T. Perkmann, M. A. Schwarz, G. Jakl, J. Wojta, and K. Huber
Complementary role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure
Eur J Heart Fail,
July 1, 2011;
13(7):
726 - 733.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Balanescu, P. Kopp, M. B. Gaskill, N. G. Morgenthaler, C. Schindler, and J. Rutishauser
Correlation of Plasma Copeptin and Vasopressin Concentrations in Hypo-, Iso-, and Hyperosmolar States
J. Clin. Endocrinol. Metab.,
April 1, 2011;
96(4):
1046 - 1052.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Fenske, C. Wanner, B. Allolio, C. Drechsler, K. Blouin, J. Lilienthal, V. Krane, and for the German Diabetes, Dialysis Study Investigat
Copeptin Levels Associate with Cardiovascular Events in Patients with ESRD and Type 2 Diabetes Mellitus
J. Am. Soc. Nephrol.,
April 1, 2011;
22(4):
782 - 790.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Masson, R. Latini, E. Carbonieri, L. Moretti, M. G. Rossi, S. Ciricugno, V. Milani, R. Marchioli, J. Struck, A. Bergmann, et al.
The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial
Eur J Heart Fail,
April 1, 2010;
12(4):
338 - 347.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Neuhold, M. Huelsmann, G. Strunk, J. Struck, C. Adlbrecht, G. Gouya, M. Elhenicky, and R. Pacher
Prognostic Value of Emerging Neurohormones in Chronic Heart Failure during Optimization of Heart Failure-Specific Therapy
Clin. Chem.,
January 1, 2010;
56(1):
121 - 126.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Maier, M. Clodi, S. Neuhold, M. Resl, M. Elhenicky, R. Prager, D. Moertl, G. Strunk, A. Luger, J. Struck, et al.
Endothelial Markers May Link Kidney Function to Cardiovascular Events in Type 2 Diabetes
Diabetes Care,
October 1, 2009;
32(10):
1890 - 1895.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B Dieplinger, A Gegenhuber, M Haltmayer, and T Mueller
Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath
Heart,
September 15, 2009;
95(18):
1508 - 1513.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Voors, S. von Haehling, S. D. Anker, H. L. Hillege, J. Struck, O. Hartmann, A. Bergmann, I. Squire, D. J. van Veldhuisen, K. Dickstein, et al.
C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study
Eur. Heart J.,
May 2, 2009;
30(10):
1187 - 1194.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.H. W. Tang and G. S. Francis
The Year in Heart Failure
J. Am. Coll. Cardiol.,
November 11, 2008;
52(20):
1671 - 1678.
[Full Text]
[PDF]
|
|
|
|
